Major Scope
- Lung Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Breast Cancer
- Prostate Cancer
- Liver Cancer
- Leukemia
- Bladder Cancer
- Kidney Cancer
- Endometrial Cancer
- Oncology Case Reports
- Radiation Therapy
Abstract
Citation: Clin Oncol. 2017;2(1):1210.DOI: 10.25107/2474-1663-v2-id1210
Mir-17-92 Cluster Dysregulation in Lymphoid Malignancies: Its Role in Limphomagenesis
Alejandro Roisman and Irma Slavutsky
Laboratory of Genetics of Lymphoid Neoplasms, Institute of Experimental Medicine, Argentina
*Correspondance to: Irma Slavutsky
PDF Full Text Editorial | Open Access
Abstract:
MicroRNAs (miRNAs) are short, endogenous singled-stranded noncoding RNAs whose dysregulation has been implicated in important biologic processes, including cancer development. The principal mechanism of action of these master regulators is to control gene expression by suppressing mRNA translation and reducing mRNA stability. In particular, the miR-17-92 cluster is one of the most frequently miRNA expressed in different subtypes of non-Hodgkin lymphomas. Its widespread dysregulation in these pathologies suggests this cluster as a new biomarker that may supplement lymphoma diagnosis and prognosis, and also as an attractive target to design novel strategies for cancer therapy.
Keywords:
Cite the Article:
Roisman A, Slavutsky I. Mir- 17-92 Cluster Dysregulation in Lymphoid Malignancies: Its Role in Limphomagenesis. Clin Oncol. 2017; 2: 1210.
Journal Basic Info
- Impact Factor: 3.231**
- H-Index: 11
- ISSN: 2474-1663
- DOI: 10.25107/2474-1663
- PubMed NLM ID: 101705590